Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?. Issue 3 (4th March 2018)

• Record Type: Journal Article
• Authors: Zhang, Yuewei; Fan, Yang; Ying, Zhitao; Song, Yuqin; Zhu, Jun; Yang, Zhi; Wang, Xuejuan
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 3(2018)
• Page Start: 660
• Page End: 669
• Publication Date: 2018-03-04
• Subjects: Diffuse large B-cell lymphoma -- PET/CT -- prognosis -- The SUVmax-liver-based interpretation; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1357171
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: In order to investigate whether the SUVmax-liver -based interpretation could improve prognostic accuracy of interim (PET-4) and posttreatment PET/CT (PET-end), 115 patients with newly diagnosed DLBCL were recruited in the study. ROC analysis revealed the optimal threshold is 1.6-fold of SUVmax-liver for PET-4 and 1.4-fold of SUVmax-liver for PET-end. The SUVmax-liver -based interpretation had a perfect interobserver agreement, higher prognostic accuracy and positive predictive value than 5-point scale and %ΔSUVmax criteria in both PET-4 and PET-end. Dramatic differences in the outcome between patients with positive and negative PET-4/PET-end were demonstrated using Kaplan–Meier survival curves ( p < .05). Univariate and multifactor analysis found PET-4 and PET-end were independent prognostic factors for the outcome of DLBCL. In conclusion, the SUVmax-liver -based interpretation were superior to 5-point scale and %ΔSUVmax criteria in analyzing the PET-4 and PET-end for the prognosis of DLBCL patients.